RegeneRx(美国)

RegeneRx

美国RegeneRx www.regenerx.comRegeneRx是一家公开上市，临床阶段的生物制药公司从事设计，研究和开发有针对性的疾病，在满足医疗需求的新型肽。RegeneRx的使命是研究和开发新的药品，保护和修复组织和器官的疾病，外伤或其他病理造成的损害。RegeneRxisapubliclytraded,clinical-stage,biopharmaceuticalcompanyen gagedinthedesign,researchanddevelopmentofnovelpeptidestargetedatdiseaseswithunmetmedicalneeds.RegeneRx’smissionistoresearchanddevelopnovelpharmaceuticalsthatprotectandrepairtissueandorgandamagecausedbydisease,traumaorotherpathology.RegeneRxacquiredtherightstoanovelpeptidefromtheNIHin1999.ThisintellectualpropertyforThymosinBeta4(Tβ4)allowedthecompanytodirectitsfocusontissueprotectionandrepairinmultiplediseaseindications.RegeneRx’smanagementteamisfocusedonmovingthreedistinctTβ4-baseddrugcandidatesthroughtheclinic:RGN-137,RGN-259andRGN-352.RegeneRxalsoholdsover60issuedpatentsorfiledpatentapplications